Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TKD/IL-2-activated autologous NK cell immunotherapy after radiochemotherapy for stage III NSCLC
2008-002130-30Phase 2Terminated
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Jun 2008
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of TKD/IL-2-activated autologous natural killer cells in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: Progression-free survival. Started Jun 2008; status: terminated.
02
Drugs
TKD/IL-2-activated autologous natural killer cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002130-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002130-30.